Company attributes
Other attributes
Lyell Immunopharma is a biotechnology company developing targeted cellular immunotherapies for treating any type of cancer that is headquartered in San Francisco, California and was founded in 2018 by Rick Klausner. The companies cellular immunotherapy products focus on using chimeric antigen receptor T (CAR-T) cells to treat solid tumors (which make up the majority of cancers). As of June 2019 the company has not publicly disclosed its official product pipeline despite receiving series A and series B funding from private investors.
On November 13, 2018 Lyell Immunopharma completed their series A funding round with an undisclosed amount of funding from undisclosed investors. The company is planning on using their series A funding for product development.
On February 8, 2019 Lyell Immunopharma completed their series B funding round with $179 million in funding from 8VC, Altitude Life Science Ventures, ARCH Venture Partners, Forsite Capital Management, and BMGI.
